Skip to search formSkip to main contentSkip to account menu

dasatinib

Known as: BMS dasatinib, Dasatinib [Chemical/Ingredient], N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide 
An orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib binds to and inhibits the growth… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Although the addition of dasatinib to letrozole improved progression-free survival in postmenopausal women with estrogen receptor… 
2011
2011
In this issue of JASN , Iyoda et al. [1][1] report that administration of nilotinib, a second-generation inhibitor of cellular… 
2010
2010
Dasatinib, a multi-kinase inhibitor that is active against BCR-ABL1 and SRC family kinases, has been reported to exert notable… 
2009
2009
A leucemia mieloide cronica (LMC) e uma neoplasia da medula ossea originada da translocacao entre os cromossomos 9 e 22 t(9:22… 
2009
2009
To the editor: Dasatinib is a novel oral multitargeted kinase inhibitor of Bcr-Abl and Src family widely used for the treatment… 
2008
2008
7012 Background: Resistance to imatinib is a well-recognized problem in CML-CP. Dasatinib is 325-fold more potent than imatinib… 
2008
2008
7055 Background: Few therapeutic options exist for patients (pts) with Philadelphia chromosome-positive (Ph+) chronic myelogenous… 
2008
2008
8568 Background: Src kinases play a major role in osteoclast function. In vitro, small molecule inhibitors of Src block… 
2006
2006
Chronic myelogenous leukemia (CML) results from a single mutagenic event leading to acquisition of the Philadelphia chromosome… 
2005
2005
The genetic heterogeneity of multiple myeloma (MM) and the evolution of the disease as it progresses result in a multiplicity of…